2cureX invited to present IndiTreat® and clinical data at ESMO in June 2018

2cureX AB (“2cureX”) announce that it has been invited to present results of the IndiTreat® clinical trial at the ESMO World Congress on Gastrointestinal Cancer 2018 in Barcelona. ESMO (European Society for Medical Oncology) is Europe’s leading medical oncology organisation with more than 18.000 oncology professionals.

The IndiTreat® trial is progressing according to plan with the first ten patients enrolled. 

The clinical trial was launched in Denmark end of October 2017 and will this year be extended to Germany (University Medical Center Hamburg-Eppendorf) and the United Kingdom (Queen Elisabeth Hospital Birmingham). The trial is directed towards patients with late stage colorectal cancer. The patients enrolled in the trial all have progressive disease with in the most cases metastasis in the liver.

This group of cancer patient have a poor prognosis and is in urgent need of identification of an efficacious treatment.

The ESMO World Congress on Gastrointestinal Cancer is by far Europe’s most important clinical conference within the colorectal cancer field, it is therefore a great pleasure for us and our clinical partners to be invited to present IndiTreat® and our clinical findings at this conference” says the CEO of 2cureX Ole Thastrup, and he continues “Colorectal cancer patients with metastatic disease are in a very difficult situation. It is urgently important to find a treatment that can arrest or even kill the growing metastasis. The clinical trial is addressing this very issue by generating a large number of micro-tumors from the patient’s liver metastasis and challenge them with a broad spectrum of treatments. The trial, being the first of its sort, is progressing positively after enrolment of the first ten patients”

IndiTreat® has been developed by 2cureX in its laboratory facilities at hospitals in Copenhagen and in Hamburg. It is the expectation by 2cureX and its clinical partners that IndiTreat® will become a standard tool for the oncologist to choose the right treatment for the individual patient.

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX. 

For more information about 2cureX:

Ole Thastrup, CEO

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99

http://www.2curex.com

About 2cureX

2cureX has developed IndiTreat® (Individual Treatment Design) - a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat® is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Tags:

About Us

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients. IndiTreat® is currently being clinically validated in colorectal and ovarian cancer. The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Subscribe

Quotes

The ESMO World Congress on Gastrointestinal Cancer is by far Europe’s most important clinical conference within the colorectal cancer field, it is therefore a great pleasure for us and our clinical partners to be invited to present IndiTreat® and our clinical findings at this conference
Ole Thastrup, CEO